173.99 0.00 (0.00%)
After hours: 4:00PM EST
|Bid||173.99 x 1000|
|Ask||173.99 x 800|
|Day's Range||168.47 - 174.18|
|52 Week Range||70.80 - 174.18|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||674.38|
|Earnings Date||Nov 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||160.57|
Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management wil
Insulet stock is the IBD Stock Of The Day after the diabetes treatment player smashed Wall Street's third-quarter estimates, raised its 2019 outlook and topped its 50-day moving average.
Dow Jones futures signal another stock market rally pause. Xerox is mulling an HP takeover. Match Group is plunging on guidance. Roku, Carvna earnings are due.
Insulet (PODD) delivered earnings and revenue surprises of 200.00% and 7.37%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced financial results for the three months ended September 30, 2019.
Encouraging growth in the emerging markets despite the ongoing Sino-US trade tensions is likely to favor revenues in the medical products space this earnings season.
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Insulet (PODD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced FDA clearance for use of Fiasp® (fast-acting insulin aspart) with the Omnipod® Insulin Management System and the Omnipod DASH™ Insulin Management System for adults. Fiasp is a new-generation, ultra fast-acting insulin developed by Novo Nordisk that enters the bloodstream two times faster than Novo Nordisk’s NovoLog®, so it more closely matches a body’s typical insulin response to a meal, thereby improving glycemic control.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2019 on November 5, 2019 after the close of the financial markets. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 3163969. Insulet Corporation (PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform.
The Massachusetts-based medical device company Insulet Corporation (NASDAQ: PODD ) said Monday that the FDA has approved its Alternate Controller Enabled Infusion, or ACE, pump. This allows Insulet to ...